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Abstract
Background and Aims: Quantitative tests of liver
function (QTLF) which are based on the hepatic me-
tabolism or clearance of test substances have been
successfully used to predict prognosis of a variety of
different liver diseases. Still sufficient data in HIV-pa-
tients under anti-retroviral therapy (ART) are lacking.
Therefore, the aim of this prospective study was to in-
vestigate if and to what extent ART influences a broad
panel of quantitative tests of liver function in patients
with HIV-infection.
Patients and Methods: Nineteen patients (14 males, 5
females, mean age 40 years) with HIV-infection under-
went QTLF including lidocaine half-life test (LHT),
galactose elimination capacity (GEC), and indocyanine
green clearance (IGC). These tests were performed
before and 3 to 6 months after initiation of anti-retro-
viral therapy. Twenty age-matched healthy, medication-
and virus-free adults served as controls.
Results: Lidocaine half-life was significantly lower in
HIV-patients without ART. Combining anti-retroviral
therapies shifted cytochrome p450 activity back into
standard ranges. Galactose elimination capacity as a
parameter of cytosolic liver function and indocyanine
green clearance as a parameter of liver perfusion were
not affected by ART.
Conclusions: QTLF may be a tool to predict prognosis
or hepatic complications in HIV-infected patients with
liver disease. Early determination of lidocaine half-life
seems to be useful - this should be considered during
the treatment of HIV-positive individuals.
Key words: anti-retroviral therapy, HIV, quantitative
tests of liver function
Abbreviations: ART, anti-retroviral therapy; GEC,
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anti-retroviral therapy; HCV, hepatitis C virus; HIV,
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INTRODUCTION
Liver toxicity is one of the most relevant adverse ef-
fect of anti-retroviral therapy (ART) in patients infect-
ed with human immunodeficiency virus type-1 (HIV-1)
(Lebovics, Thung et al. 1985; Schneiderman, Arenson
et al. 1987). Although there are many other causes of
liver disease in these patients (Farrell 2002), the most
common are viral co-infections, drugs and narcotics,
which are most prominent upon treatment with highly
active anti-retroviral therapy (HAART). Likewise, both
nucleoside reverse transcriptase inhibitors (NRTI) and
protease inhibitors (PI) are associated with metabolic
alterations and disorders, such as liver toxicity, lipodys-
trophy and insulin resistance (Ena, Amador et al. 2003;
Lee, Seneviratne et al. 2004). The spectrum of liver
damage in this population ranges from simple hepatic
steatosis to steatohepatitis and even fibrosis (Clark,
Brancati et al. 2002). Most patients with hepatic alter-
ations are asymptomatic, and liver disease may unex-
pectedly be diagnosed during the evaluation of unex-
plained persistent elevations of serum liver enzymes.
In this case, and once other known aetiologies have
been ruled out, imaging procedures often suggest fatty
infiltration of the liver parenchyma (Yano, Tagawa et
al. 2001). Since most of these patients are indolent,
fatty liver seems to be a benign and stable disease
(Reid 2001). Nevertheless, sensitizing the liver may
lead to acute-on-chronic liver failure (Kahraman,
Miller et al. 2006) or cryptogenic cirrhosis with the
necessity of liver transplantation. Consequently, it is of
major clinical importance to assess stage and progno-
sis of liver disease in HIV-positive patients.
Conventional serum parameters (e. g., coagulation
factors, albumin or cholinesterase) often lack sensitivity
in early stages of liver disease and are mostly changed
in advanced stages. However, the available routine lab-
oratory tests only reflect individual facets of liver in-
jury, synthetic capability or a pre-existing disease. They
are not able to identify patients with marginal liver
function. Various laboratory data and imaging tech-
niques have been used to complement the Child-Tur-
cotte-Pugh or the MELD score to predict severity of
liver disease and assess functional hepatic reserve.
Therefore, quantitative tests of liver function (QTLF)
may be a useful diagnostic tool to predict prognosis
and outcome of liver disease in HIV-infected patients
under anti-retroviral therapy, and they may be useful to
search for drugs that restore liver function.
Quantitative or dynamic liver function tests were in-
troduced in the middle of the last century (Bradley, In-
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gelfinger et al. 1945; Leevy, Mendenhall et al. 1962;
Tygstrup 1963). They measure the turn-over or elimi-
nation of an exogenous test substance that is exclu-
sively metabolized and eliminated by the liver, and have
helped to elucidate the structure-function relationship
of the liver. Furthermore, they have been shown to
have a prognostic value independent of and often su-
perior to that of scores like the Child-Turcotte-Pugh or
the recently used MELD score (Reichen 1995). All
quantitative tests are based on the hepatic clearance
principle. The clearance of the test substance is deter-
mined by the liver blood flow via the portal vein and
the hepatic artery, as well as by the degree to which this
test substance is extracted by the liver, whereas the fi-
nal elimination depends on the hepatic metabolic ca-
pacity. Depending on the administered compound, it is
possible to separately analyze microsomal (e. g., amino-
pyrine, caffeine, erythromycin, methacetin, phenacetin),
cytosolic (galactose, phenylalanine) or mitochondrial
(α-ketoisocaproicacid,methionine)metabolicpathways.
Most available data come from microsomal function
tests; data about cytosolic and mitochondrial liver func-
tion are more limited. The effects of liver perfusion-de-
pendent metabolism, induction or inhibition of cyto-
chrome p450, nutrition or age provide little dependable
information to evaluate functional liver mass (Armuzzi,
Candelli et al. 2002; Schneider, Caspary et al. 2004).
QTLF include for example the lidocaine half-life
test (LHT), the galactose elimination capacity (GEC),
and the indocyanine green clearance (IGC). LHT re-
flects the function of the cytochrome p450 system and
the quality of detoxification of liver cells (Lamesch,
Ringe et al. 1990; Reichel, Wienkoop et al. 1995;
Reichel, Wienkoop et al. 1995; Jochum, Beste et al.
2006). Disappearance of lidocaine is dependent upon
liver perfusion as well as metabolism by different cyto-
chrome p450 isoenzymes. GEC reveals the metabolic
liver function (Tygstrup 1966; Tygstrup, Andersen et al.
1985; Keiding 1987) whereas IGC provides informa-
tion about the hepatic perfusion and the excretion out-
put of the bile, at least in healthy livers (Leevy,
Mendenhall et al. 1962; Meijer, Weert et al. 1988;
Plevris, Jalan et al. 1999; Ott, Clemmesen et al. 2000).
So far, data about QTLF are existent for patients
with liver cirrhosis due to chronic HCV-infection to as-
sess disease severity, for patients with liver cirrhosis to
discriminate between different aetiologies, for patients
with chronic hepatitis B and C co-infection in relation
to fibrosis, for patients with non-cirrhotic chronic he-
patitis C-infection to predict portal vein velocity, and
finally for living liver donors and their recipients to as-
sess functional hepatic reserve (Herold, Berg et al.
2000; Herold, Heinz et al. 2001; Herold, Heinz et al.
2001; Herold, Ganslmayer et al. 2002; Herold, Regn et
al. 2002; Herold, Ganslmayer et al. 2003; Jochum,
Beste et al. 2006; Reichen 2006). However, still suffi-
cient data in HIV-patients comparing several quantita-
tive tests of liver function are lacking, and to date no
clinical study has been carried out to assess the values
of these tests in patients with HIV-infection. We there-
fore tested the hypothesis if liver function might be re-
stored in patients with HIV-infection following anti-
retroviral therapy. Here, we investigated if and to what
extent changes in either hepatic metabolic enzyme
function and in liver perfusion can be achieved by anti-
retroviral therapy, and also if changes in QTLF may
help to discriminate responders from non-responders
to anti-viral treatment strategies in patients with HIV-
infection. We applied the panel of LHT, GEC and IGC
to 19 patients with HIV-infection under therapy with
different anti-viral regimes and compared these results
to a healthy, medication- and virus-free control group.
Beside the evaluation of the liver function under anti-
retroviral therapy, we especially paid attention to the
liver function of HIV-patients with HCV co-infection
under ART since infection with the more liver-specific
HCV can compromise liver function.
PATIENTS AND METHODS
Patients: Nineteen consecutive patients of all risk
classes (14 males and 5 females, mean age 40 ±1 1 . 3
years) with HIV-infection were included in this
prospective study (Table 1). Among these HIV-pa-
tients, 6 were classified C3, 9 were classified B1/2, and
finally, 4 were classified A1/2 according to the CDC-
classification of 1993. Values for CD4+ T cells were
between 70 to 1200/µl and viral load ranged between
< 50 to 360.000 copies/ml. Moreover, 7 of these pa-
tients had a HCVco-infection. Three patients were trea-
Table 1. Demographic and clinical characteristics of patients and controls investigated in the study.
Healthy controls
(n = 20)
Patients with HIV
(n = 19)
G e n d e rr a t i o m:f=1 5:5 m:f=1 4:5
Age (yrs.)
Weight (kg)
Height (cm)
BMI (kg/m2)
AST (mg/dl)
ALT (mg/dl)
Total bilirubin (mg/dl)
γ-GT
42.1 ± 7.5
69.7 ± 16.1
171.4 ± 11.5
2 2 . 5±1 . 3
24.5 ± 1.7
28.7 ± 2.8
0.5 ± 0.3
52.1 ± 5.2
40 ± 11.3
64 ± 17.4
174.7 ± 11.5
1 9 . 6±4 . 6
29 ± 11.3
27.3 ± 17.2
0.5 ± 0.2
97.8 ± 11.5
HCV co-infection none 7371 September 1, 2009 EUROPEAN JOURNAL OF MEDICAL RESEARCH
ted with NRTI (nucleoside reverse transcription inhibi-
tor)alone, 4 with NRTI+ PI (protease inhibitor), 4 with
NRTI + NNRTI (non-NRTI), 5 with NRTI + NNRTI
+ PI, and finally, 3 patients were without ART. Chronic
alcohol abuse was not observed in any of these patients
(<60 g/day in men and <30 g/day in women). Patients
other than Caucasian origin, age < 18 or > 65 years,
active drug abuse, and other causes of liver disease were
excluded. In addition to exploration of the case history
and the clinical status, chemical laboratory values were
determined for all HIV-patients. Twenty age- and gen-
der-matched healthy, medication- and virus-free adults
served as controls (15 males and 5 females, mean age
42.1 ± 7.5 years), and all values of QTLF in HIV-
patients were correlated with the normal values of this
group (Table 1). To assess the condition of the liver in
the control group, several liver parameters including
serum transaminases, total bilirubin, γ-GT, serum bile
acids, albumin, and routine coagulation tests were de-
termined, which were within normal ranges.
All patients underwent QTLF before and 3 to 6
months after the initiation of anti-retroviral therapy.
The current study was performed in accordance to the
ethical standards formulated in the version of the
1964 Declaration of Helsinki. All patients gave their
informed consent prior to inclusion in this present
study. Before performance of the QTLF, all drugs
(e. g., barbiturates, benzodiazepines, anti-depressive
drugs, H2-blockers, grapefruit juice, etc.) that could po-
tentially interfere with liver function were discontinued
in both groups 4 weeks in advance.
Measurement and calculation of LHT, GEC and
IGC: The following three pharmacokinetic tests were
performed to quantitatively assess changes in liver
function during anti-retroviral therapy for each pa-
tient. Briefly, lidocaine (xylocaine 2 %, Firma Astra,
Wedel, Germany) was given as a single bolus injection
of 1 mg/kg body weight over 2 minutes, 5 ml blood
samples were obtained from a peripheral vein at 30, 60,
120, 180, 240, and finally 300 min., and detected in
the serum using the Fluorescence Polarization Im-
munoassay Method by the Abbott TDX-System (Fir-
ma Abbott, Wiesbaden, Germany). Lidocaine concen-
trations were expressed in µg/ml and were calculated
against an internal calibration curve. Background con-
centrations measured before infusion of lidocaine
were subtracted from all results. The assay used had a
limit of detection of 5 ng/ml. Lidocaine half-life was
expressed in minutes.
To determine GEC, galactose (Pharmaceutical Insti-
tute, University of Essen, Germany) was injected intra-
venously as a bolus (45 % galactose, 0.5 g/kg body
weight), which saturates the catabolic enzyme system.
The speed at which elimination of galactose takes place
is determined by its phosphorylation by galactokinase
which is located in the hepatic cytoplasm. Serum sam-
ples were treated with 1 ml of 0.33 M perchloric acid
per 200 µl serum and centrifuged at 2.400 g. The super-
natant was analyzed using the Enzymatic Test Kit
Galactose (Firma Roche Diagnostics GmbH, Mann-
heim, Germany). Urine was collected over a period of 5
hours after injection of galactose. The volume of the
collected urine was measured, and for calculation of
GEC at time point 0 and from 20 to 60 minutes (5-
minutes intervals), serum concentrations of galactose
were determined photospectrometrically (PM6, Firma
Zeiss, Oberkochem, Germany) at 366 nm. GEC was
calculated using the following formula: (infusion dose
[g] galactose - galactose in urine [g])/(time at concen-
tration 0 + infusion time) x 1.000/kg body weight. The
results were expressed as mg/kg/minute.
IGC is absorbed exclusively by the liver and, if
there is a high hepatic elimination rate, the substrate is
quickly excreted in a mostly unmodified form by 97 %
in the bile. Therefore, IGC is influenced both by the
biliary secretion capacity and by the liver perfusion. In
addition, IGC is considered to be insensitive to phar-
macological influences because its metabolism solely
depends on the hepatic transport and biliary secretion.
This test is the most widely used clearance test for liv-
er diseases. Nevertheless, it remains imperfect because
it depends both on the hepatic blood flow and on the
functional capacity of the liver. IGC (Cardio Green,
Firma Paesel, Hamburg, Germany) is also injected in-
travenously as a bolus of 0.5 mg/kg body weight.
Serum concentrations were also measured photospec-
trometrically at 800 nm every 3 minutes until 21 min-
utes post-injection. Values were expressed as half-life
in minutes. Serum transaminase levels, parameters of
cholestasis, and coagulation factors were determined by
routine methods at the Department of Medical Chem-
istry, University of Essen.
Statistical Analysis: All data are expressed as the
mean ± standard error unless otherwise indicated. For
statistical analyses, the Mann-Whitney U test for unre-
lated groups was used to compare HIV-patients and
healthy controls at different time points. For compari-
son within these 2 groups at different time points, we
used the Wilcoxon test for connected samples. Differ-
ences between groups were compared using analysis of
variance (ANOVA) for repeated measures and post-hoc
Bonferroni test to correct for multiple comparisons. Cal-
culations were made using Microsoft Excel software
and publicly available internet sources (In-Stat Soft-
ware, Graph Pad, San Diego, California). A p value
less than 0.05 was considered to be statistically signifi-
cant compared to the controls.
RESULTS
Lidocaine half-life is significantly lower in HIV-
positive patients without ART: We first investigated
the influence of different anti-retroviral regimens on
lidocaine half-life. As demonstrated in Figure 1A, in
healthy controls and in HIV-positive patients without
ART lidocaine half-life was significantly lower than in
each treated sub-group of patients with HIV-infection -
suggesting a higher activation of the cytochrome p450
system. Lidocaine half-life was measured before initia-
tion and after 6 months of treatment. HIV-positive pa-
tients treated for 6 months with anti-retroviral therapy
had a prolonged lidocaine half-life as compared to the de-
creased values in the HIV-infected naïve group. Lido-
caine half-life before the initiation of ART is also de-
picted. This increased activation in treated patients with
HIV-infection might be a virus-induced effect. In addi-
tion, combining anti-retroviral therapies (Triple-Nuc,
NRTI + NNRTI or NRTI + PI) shifted cytochrome372 EUROPEAN JOURNAL OF MEDICAL RESEARCH September 1, 2009
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Fig. 1. Measurement of lidocaine half-life
before and after initiation of therapy in
HIV-patients with various anti-viral regi-
mens: A. Lidocaine half-life - expressed
in minutes - was significantly lower in
HIV-patients without ART. * p < 0.05, n
= patients’ number. B. Lidocaine half-life
- measured 3 and 6 months (mo.) after
initiation of ART - was almost identical
with no obvious changes under anti-
retroviral treatment in patients with HIV-
infection. C. Hepatitis C co-infection in
HIV-patients had no significant influence
on lidocaine half-life and activity of cy-
tochrome p450.373 September 1, 2009 EUROPEAN JOURNAL OF MEDICAL RESEARCH
Table 2. Markers of liver function in HIV-patients with and without HCV co-infection (n = patients’ number).
HIV with HCV co-infection HIV without HCV co-infection p-value
( n=5 ) ( n=5 )
ALT (U/l) 62.6 ± 21.14 41.65 ± 9.75 0.39
AST (U/l) 42.7 ± 9 22.55 ± 3.77 0.021
γ-GT (U/l) 138.8 ± 43.27 61.15 ± 17.32 0.056
Bilirubin (mg/dl) 0.94 ± 0.27 0.59 ± 0.07 0.083
CHE (U/l) 5.16 ± 0.77 6.21 ± 0.36 0.25
p450 activity back into standard ranges. Interestingly,
no obvious differences according to the various ART
combinations could be demonstrated.
Lidocaine half-life test following ART was only
marginally changed during the course of six
months: Next, we investigated if and to what extent
lidocaine half-life changed in HIV-patients upon treat-
ment with ART for both 3 and 6 months. Lidocaine
half-life test was performed in 10 randomly selected pa-
tients out of 19 with HIV-infection. As shown in Fig-
ure 1B, lidocaine half-life was insignificantly changed
before the initiation of anti-retroviral therapy and dur-
ing the follow-up examination, and decreased from
161.5 (range 82-304) to 154.7 (range 85-341) min-
utes (p = 0.84). Further, lidocaine half-life test showed
no significant changes during the follow-up examination
in patients with HIV-infection as compared to the
healthy control (range 90-322 minutes).
The monoethylglycinexylidide (MEGX) test is a dy-
namic test based on the conversion of lidocaine to
MEGX primarily by cytochrome p450 3A4
tal bilirubin, and cholinesterase (CHE) revealed signifi-
c a n tc h a n g e so n l yf o rA S Tv a l u e si nH I V - i n f e c t e dp a -
tients with HCV co-infection as compared to HIV-pa-
tients without hepatitis C infection (Table 2).
Indocyanine green clearance was unaffected by
different anti-retroviral medications in HIV-pa-
tients: Indocyanine green clearance was performed before
and 6 months after initiation of HAART to investigate
the correlation between hepatic perfusion and different
anti-retroviral regimens in patients with HIV-infection.
Three HIV-patients were without ART, 3 further pa-
tients were either treated with NRTI or with NRTI in
combination with PI, 4 patients were treated with
NRTI + NNRTI, and finally, 5 patients were treated
with the combination of NRTI + NNRTI + PI. As
depicted in Figure 2A and B, no correlation could be
found between indocyanine green clearance and various
anti-retroviral regimens in HIV-patients.
(CYP3A4). Losses of hepatic CYP450 3A4 activity or
changes in hepatic blood flow result in decreased MEGX
formation. Previous studies have revealed that the
MEGX test is an effective tool for assessing liver func-
tion and furthermore, this test has a high reliability
when repeated (Oellerich and Armstrong 2001). We
therefore investigated the prognostic value of the MEGX
test in our study population. The test was performed be-
fore and 6 months after the initiation of ART, and re-
sults were compared to values obtained from healthy con-
trols. However, we found no significant changes in HIV-
patients treated with various combinations as compared
to healthy controls without medication (49.9 ± 25.48
µg/l versus 66.29 ± 38.55 µg/l, p = 0.23).
Co-infection with hepatitis C virus in patients with
HIV-infection had no influence on lidocaine half-
life and activity of cytochrome p450: Within the 19
HIV-patients in our study, 5 of them were co-infected
with HCV. Six patients had a former hepatitis B-, and 2
patients had a former hepatitis B- and C co-infection
(Fig. 1C). Lidocaine half-life in dependence to HCV co-
infection was only slightly increased but not significantly
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affected, suggesting that hepatitis C infection might be
negligible on the liver function of HIV-patients, and is
not a contra-indication for anti-retroviral therapy, al-
though hepatitis C virus is more liver specific and can
compromise quality of liver function. However, this re-
sult should be interpreted with caution because of the
Fig. 2. Indocyanine green clearance - as a parameter of biliary
secretion capacity and liver perfusion - was not dependent on
the different anti-retroviral regimens in patients with HIV-in-
fection. IGC is expressed as mg/kg; n=p a t i e n t s ’n u m b e r .A .
Determination of IGC before initiation of HAART. B. Deter-
limited number of patients investigated. Determination of mination and course of IGC after 6 months of anti-retroviral
other markers of liver function such as transaminases, to- treatment.374 EUROPEAN JOURNAL OF MEDICAL RESEARCH September 1, 2009
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Galactose elimination capacity in HIV-patients
was not influenced by ART: To test if metabolic liv-
er function is improved in HIV-patients under ART,
GEC was performed in non-treated patients with
HIV-infection, and values were then compared to the
values of treated patients. Again, as demonstrated be-
fore for the indocyanine green clearance, no significant dif-
ferences were observed between HIV-patients before and
after the initiation of anti-retroviral therapy (Fig. 3A).
Galactose elimination capacity in HIV-patients was
unaffected by co-infection with hepatitis C virus. Fife
out of 19 patients with HIV-infection were co-infected
with hepatitis C virus (Fig. 3B). During anti-retroviral
therapy, values for GEC changed only marginal from
7.7 mg/kg/min. in HIV-patients without HCV co-in-
fection as compared to 5.75 mg/kg/min. in HIV-pa-
tients with hepatitis C co-infection. GEC was appar-
ently reduced in patients with HIV-HCV co-infection
indicating a reduction of cytosolic liver function. How-
ever, this reduction was statistically not significant.
C
Fig. 3. Measurement of GEC in patients with HIV-infection:
A. Galactose elimination capacity - determined before and 6
m o n t h sa f t e ri n i t i a t i o no fA R T-w a sn o ti n f l u e n c e db yv a r i o u s
anti-retroviral regimens. B. GEC was not significantly reduced
during co-infection with hepatitis C virus. C. The metabolic
liver capacity oscillated under long-term therapy for 3 to 6
months remained unchanged without obvious tendency.
PAT = patients’ number; GEKDIF = differences in GEC.
Galactoseeliminationcapacityremained unchanged
during the course of anti-retroviral treatment: In
our final experiment, 10 randomly selected patients with
HIV-infection had a follow-up examination after 3 to 6
months of treatment with anti-retroviral therapy. As
demonstrated in Figure 3C, the metabolic liver capacity
oscillated during this long-term therapy was mainly un-
changed without obvious tendency.
DISCUSSION
Hepatic steatosis is a common feature developing
upon application of state-of-the-art anti-retroviral
regimens, including nucleoside reverse transcriptase
inhibitors (NRTI), non-NRTIs and protease in-
hibitors. Still, severe hepatotoxicity is a rare event.
However, with the increasing employment of
HAART in developed countries, hepatic steatosis and
severe hepatotoxicity with acute liver failure may be
seen more often among patients with HIV-infection375 September 1, 2009 EUROPEAN JOURNAL OF MEDICAL RESEARCH
(Montessori, Harris et al. 2003; Kahraman, Miller et
al. 2006).
The substantial survival benefit of HAART in the
treatment of patients infected with HIV-1 has been
frequently documented, revealing both a reduction in
morbidity and mortality as well as a significant im-
provement in the quality of life (Lipsky 1996; Ristig,
Drechsler et al. 2005). Still, alongside the benefits of
these treatments, HAART-associated adverse events
become increasingly apparent. These ranged from
mild side-effects, such as abdominal pain, polyneu-
ropathy or elevated liver enzymes to severe life-threat-
ening complications, such as acute liver failure, pancre-
atitis, and lactic acidosis.
Quantitative tests of liver function may allow a
prognostic assessment of patients with various liver
diseases (Herold, Berg et al. 2000; Herold, Heinz et al.
2001; Herold, Heinz et al. 2001; Herold, Ganslmayer
et al. 2002; Herold, Regn et al. 2002; Herold, Gansl-
mayer et al. 2003; Jochum, Beste et al. 2006; Reichen
2006). Although transaminases - the commonly used
markers of hepatocellular injury - have a high sensitivi-
ty in screening for liver diseases, they do not provide any
information about prognosis. In addition, assessment of
liver function using bilirubin, serum albumin and pro-
thrombin-time is limited by their inability to identify the
functional reserve of the liver. Dynamic liver function
tests are therefore an improvement on the static tests.
They are cost-effective, easy to perform and analyse, safe,
have a simple pharmacokinetic profile with minimal
drug interactions, have a high predictive value, and fi-
nally, provide quick results (Jalan and Hayes 1995;
Candelli, Cazzato et al. 2004). The value of these
tests has been demonstrated for patients with acute re-
duction of the hepatic metabolic capacity, such as in
fulminant liver failure and alcoholic hepatitis (Merkel,
Bolognesi et al. 1989). However, the value of QTLF in
patients infected with HIV is debatable, since parame-
ters of QTLF could be influenced by different co-fac-
tors such as anti-viral drug administration, viral co-in-
fections, and age. Still, there is insufficient data about
these patients and a comparison of various QTLF is
still lacking. Recent studies have described changes of
a single QTLF in patients with chronic hepatitis C-in-
fection receiving interferon therapy (Ocker, Ganslmay-
er et al. 2005).
In the present study, we determined a panel of
three QTLF and, when compared to a healthy control,
lidocaine half-life as a parameter of detoxification
quality of hepatocytes was found to be significantly
reduced in HIV-positive patients without anti-retrovi-
ral treatment. A number of medications that are com-
monly used in HAART regimens are metabolized by the
hepatic CYP enzymes, which raises the possibility of
significant interactions between anti-retroviral medica-
tions and hepatic impairment. The cytochrome p450
isoenzyme CYP1A2 is the main isoform responsible for
lidocaine biotransformation. In HIV-positive patients
protease inhibitors (for example lopinavir/ ritonavir)
can lead to the induction of CYP1A2 which may inter-
act with lidocaine metabolism (Orlando, Piccoli et al.
2004; Wyles and Gerber 2005). We conclude that mea-
suring LHT may be a tool to predict prognosis or com-
plications in HIV-infected patients with liver disease,
and may help to discriminate positive patients’ response
from negative response. In HIV-positive patients with
compromised liver function this might help to modify
anti-retroviral therapy and switch to drugs that are less
hepatotoxic.
Severe hepatotoxicity in HIV-infected patients receiv-
ing HAART occurs in 5 - 10 % of cases. The main
risk factors are viral co-infections, advanced liver dis-
ease, and elevated liver enzymes at the start of therapy.
Anti-retroviral drugs associated with an increased risk
of severe hepatotoxicity are stavudine, didanosine, nevi-
rapine, full-dose ritonavir and tipranavir (Vogel and
Rockstroh 2005; Vogel and Rockstroh 2007). We ob-
served an increase in the activity of cytochrome p450 in
HIV-positive patients with different ART regimes -
which might be a virus- or a drug-induced effect. Com-
bining anti-retroviral therapies shifted cytochrome p450
activity back into standard ranges. However, the differ-
ent components of HAART are each associated with
risks of liver toxicity. Most drugs are metabolized by
cytochrome p450 enzymes in the liver, and this may be
affected by liver disease. The mechanisms for drug-in-
duced liver injury include dose-dependent toxicity, idio-
syncratic reactions, mitochondrial toxicity, and immune
reconstitution. Once diagnosed, management generally
involves discontinuation of the offending anti-retroviral
drugs. Therefore, QTLF may provide important prog-
nostic informations in patients with HIV-related liver
disease and tolerability of HAART (Inductivo-Yu and
Bonacini 2008).
Activation of the cytochrome p450 system showed no
essential differences in HIV-patients with HCV co-in-
fection. However, this co-infection seems to be negligible
on liver function, and is not a contra-indication for
ART. Ocker and colleagues investigated to what extent
anti-viral therapy influenced QTLF in patients with
HCV-infection. Patients with HIV co-infection were
unfortunately excluded from the study. Tests were per-
formed before and 3 months after the initiation of ther-
apy. They demonstrated that parameters of microsomal
and cytosolic liver function were reduced in all patients
before therapy initiation and returned to normal values
in therapy responders after 3 months. Parameters of liv-
er perfusion were not affected by anti-viral therapy. Ac-
cording to the authors, early determination of GEC
may differentiate responders from non-responders to
anti-viral treatment in patients with hepatitis C-infec-
tion (Ocker, Ganslmayer et al. 2005). In a further
study, Herold et al. applied a broad panel of QTLF to
patients with hepatitis B and C-infection. Again, pa-
tients with HIV co-infection were unfortunately not in-
cluded in the study. All QTLF values were correlated
with liver histology and Child-Pugh classification for
liver cirrhosis. The authors could demonstrate that in
patients with moderate fibrosis, metabolic liver function
was significantly decreased whereas hepatic perfusion re-
mained normal. Severe fibrosis and cirrhosis showed a
significant decline in all QTLF. Viral aetiology and
HCV genotypes did not change QTLF (Herold, Heinz
et al. 2001).
In our present study, parameters of the cytosolic
metabolic capacity, liver perfusion and secretion were
not compromised in non-treated versus treated pa-
tients with HIV-infection. We examined IGC and376 EUROPEAN JOURNAL OF MEDICAL RESEARCH September 1, 2009
GEC and found no significant correlation. Therefore,
we conclude that viral damage to the liver compromis-
es quality of liver detoxification before metabolic ca-
pacity and hepatic perfusion. The great variability of
GEC within HIV-infected patients might be related to
the small number of patients investigated in this study
or to different anti-viral regimens. So far, no data exist
about impact of different components of HAART on
GEC. Compared to treated patients with HIV-infec-
tion, we found a significant reduction in lidocaine half-
life before the initiation of anti-retroviral therapy.
However, we found no significant influence of hepatitis
C co-infection although infection with hepatotropic virus-
es affects liver function. The reason is obviously the
small number of patients investigated with HIV-HCV
co-infection.
Until now, QTLF have not been validated in pa-
tients with HIV-infection. At present, it remains un-
clear if and how far QTLF may provide important
prognostic informations in patients with HIV-related
liver diseases that is superior to that of conventional
prognostic parameters or risk scores. Our current
study suggests that certain QTLF could be useful to
monitor the effect of anti-retroviral or liver-protective
therapy in patients with liver disease caused by HIV-
infection and additionally, it may be an economical
method to follow up these patients - particularly those
under treatment with ART. Repeated measurements of
lidocaine half-life with a simple device can predict the
outcome and therefore, might be clinically useful in
following patients with HIV-infection. For example,
assessment of IGC removal has been demonstrated in
many different clinical settings to have major predic-
tive power with respect to morbidity and mortality
(Reichen 1995). It is well known that all anti-retroviral
drug classes, nucleoside/nucleotide reverse transcriptase
inhibitors (NRTI), non-nucleoside reverse transcriptase
inhibitors (NNRTI), and protease inhibitors (PI) may
cause hepatotoxicity but in different pathways (Abres-
cia, D'Abbraccio et al. 2005). However, in our experi-
ments we did not observe significant changes in quantita-
tive liver tests in dependence to diverse anti-retroviral
regimens. So far, we evaluated only a small group of
HIV-patients. Since QTLF could be useful to monitor
anti-retroviral therapy in patients with HIV-infection
and regarding the increasing role of liver-related mor-
bidity and mortality in HIV-infected patients,m o r e
prospective randomized, controlled trials with a larger
number of patients are justified.
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